Ranibizumab injection and TTT - ICG based — Competitive Intelligence Brief

Ranibizumab injection and TTT - ICG based (Ranibizumab injection and TTT - ICG based) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance. Area: Ophthalmology.

phase 3 VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance VEGF-A Ophthalmology Small molecule

Target snapshot

Ranibizumab injection and TTT - ICG based (Ranibizumab injection and TTT - ICG based) — New England Retina Associates. Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ranibizumab injection and TTT - ICG based TARGET	Ranibizumab injection and TTT - ICG based	New England Retina Associates	phase 3	VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance	VEGF-A
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
intravitreal ranibizumab injections	intravitreal ranibizumab injections	Hospital Regional de São José - Dr. Homero de Miranda Gomes	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance class)

1. New England Retina Associates · 1 drug in this class